title: [Effects of jin chai antiviral capsule on IFITM3 expression in mice].
abstract: This study is to investigate the treatment of Jin Chai antiviral capsule for influenza virus FM1/47 (H1N1) infection. The model of pneumonia was established by dropping influenza virus into the nose of normal mice, real-time PCR and Western blot technique were used to detect the virus load and the interferoninducible transmembrane protein3 (IFITM3) in lung of mice at the 1st day, 3rd day, 5th day and 7th day after affected. The results showed that Jin Chai antiviral capsule in large, middle, small dose groups can decrease virus load significantly at each time point, after being affected (P<0.05, P<0.01), Jin Chai antiviral capsule can increase the interferoninducible transmembrane protein3 in lung of mice, large dose groups are significantly higher in expression of IFITM3 compared with model group at each time point (P<0.05, P<0.01). Middle dose groups are significantly higher in expression of IFITM3 compared with model group at the 3th day and the 5th day (P<0.05), small dose groups are significantly higher in expression of IFITM3 compared with model group at the 3th day (P<0.05). It can be concluded that Jin Chai antiviral capsule exerts antiviral effects against influenzavirus by raised expression of IFITM3.
authors.affiliation: Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
authors.forename: Ju-Ying
authors.initials: JY
authors.lastname: Zhong
authors.forename: Xiao-Lan
authors.initials: XL
authors.lastname: Cui
authors.forename: Yu-Jing
authors.initials: YJ
authors.lastname: Shi
authors.forename: Shan-Shan
authors.initials: SS
authors.lastname: Guo
authors.forename: Ying
authors.initials: Y
authors.lastname: Liu
authors.forename: Fang-Zhou
authors.initials: FZ
authors.lastname: Liu
authors.forename: Ying-Jie
authors.initials: YJ
authors.lastname: Gao
authors.forename: Ya-Hong
authors.initials: YH
authors.lastname: Jin
authors.forename: Hong-Xin
authors.initials: HX
authors.lastname: Cao
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002214:Capsules; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects; D008168:Lung / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism*; D051379:Mice; D008813:Mice, Inbred ICR; D009976:Orthomyxoviridae Infections / Q000378:metabolism* / Q000821:virology; D010946:Plants, Medicinal / Q000737:chemistry; D011014:Pneumonia / Q000378:metabolism* / Q000821:virology; D019562:Viral Load / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D002214:Capsules; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D008565:Membrane Proteins; C462181:fragilis protein, mouse